ANDA 204111, held by Macleods Pharms. Aripiprazole.
As of Nov 16, 2026, ANDA 204111 (Aripiprazole), held by Macleods Pharms, was first approved by FDA on Oct 7, 2016, with 1 approved supplement and 0 published complete response letters.
Aripiprazole Tablets are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 7, 2016 | Original application | Approved | None posted |
| Aripiprazole2MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole5MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole10MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole15MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole20MG · tablet;oral | Aripiprazole | Rx |
| Aripiprazole30MG · tablet;oral | Aripiprazole | Rx |
| Jun 7, 2023 | Supplement 17Labeling · Standard review | Approved | None posted |
| Oct 7, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters